Priovant nabs first FDA approval for targeted tablet in dermatomyositis
RegulatoryapprovedLisrayaPositive
AI Analysis
Summary
Priovant received first FDA approval for Lisraya, a targeted tablet for treating dermatomyositis in adults. The drug carries a standard JAK inhibitor boxed warning but has a broad label expected to support blockbuster sales potential.
Outcome Details
First FDA approval for targeted tablet in dermatomyositis; carries boxed warning typical of JAK inhibitors; broad label allowing use in all adults with the rare autoimmune disease
Importance:8/10
Sentiment:
0.90
FDA approvalJAK inhibitordermatomyositisrare diseaseLisraya
Related Companies
Read the original article
Published by BioSpace on August 28, 2026 12:10 PM